146 related articles for article (PubMed ID: 34920804)
21. Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden.
Uttervall K; Tätting L; Lemonakis K; Majd M; Crafoord J; Olsson M; Mellqvist UH; Hansson M; Nahi H
Cancer Med; 2024 Apr; 13(8):e7048. PubMed ID: 38651177
[TBL] [Abstract][Full Text] [Related]
22. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.
Palecki J; Bhasin A; Bernstein A; Mille PJ; Tester WJ; Kelly WK; Zarrabi KK
Cancer Biol Ther; 2024 Dec; 25(1):2356820. PubMed ID: 38801069
[TBL] [Abstract][Full Text] [Related]
23. Understanding Infection Risk with Anti-BCMA Bispecific Antibodies.
Garfall AL; Stadtmauer EA
Blood Cancer Discov; 2023 Nov; 4(6):427-429. PubMed ID: 37769160
[TBL] [Abstract][Full Text] [Related]
24. Reinforced antimyeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with bridging-BiTE.
Konishi T; Ochi T; Maruta M; Tanimoto K; Miyazaki Y; Iwamoto C; Saitou T; Imamura T; Yasukawa M; Takenaka K
Blood; 2023 Nov; 142(21):1789-1805. PubMed ID: 37738633
[TBL] [Abstract][Full Text] [Related]
25. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment.
Guo X; Wu Y; Xue Y; Xie N; Shen G
Front Immunol; 2023; 14():1291836. PubMed ID: 38106416
[TBL] [Abstract][Full Text] [Related]
26. Activated neutrophils as effector cells for bispecific antibodies.
Valerius T; Würflein D; Stockmeyer B; Repp R; Kalden JR; Gramatzki M
Cancer Immunol Immunother; 1997; 45(3-4):142-5. PubMed ID: 9435858
[No Abstract] [Full Text] [Related]
27. Clinical perspectives of bispecific antibodies in cancer.
de Gast GC; van de Winkel JG; Bast BE
Cancer Immunol Immunother; 1997; 45(3-4):121-3. PubMed ID: 9435853
[No Abstract] [Full Text] [Related]
28. T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma.
Verkleij CPM; O'Neill CA; Broekmans MEC; Frerichs KA; Bruins WSC; Duetz C; Kruyswijk S; Baglio SR; Skerget S; Montes de Oca R; Zweegman S; Verona RI; Mutis T; van de Donk NWCJ
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38687588
[TBL] [Abstract][Full Text] [Related]
29. IgG-VHH bispecific fusion antibodies: challenges and opportunities as therapeutic agents.
Madsen AV; Kristensen P; Goletz S
Expert Opin Biol Ther; 2024 Apr; 24(4):203-206. PubMed ID: 38544310
[No Abstract] [Full Text] [Related]
30. [Current status and future perspective of clinical trials for patients with multiple myeloma].
Suzuki T; Maruyama D
Rinsho Ketsueki; 2024; 65(5):420-427. PubMed ID: 38825522
[TBL] [Abstract][Full Text] [Related]
31. Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed
Noguchi Y; Yan M; Tachi T; Yoshimura T
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649281
[No Abstract] [Full Text] [Related]
32. [Talquetamab - multiple myeloma after at least three prior lines of therapy].
Fatrara T; Chalayer E
Bull Cancer; 2024 Apr; 111(4):336-337. PubMed ID: 38458925
[No Abstract] [Full Text] [Related]
33. Immune status and selection of patients for immunotherapy in myeloma: a proposal.
Dhodapkar MV
Blood Adv; 2024 May; 8(10):2424-2432. PubMed ID: 38564776
[TBL] [Abstract][Full Text] [Related]
34. Structure and function of therapeutic antibodies approved by the US FDA in 2023.
Strohl WR
Antib Ther; 2024 Apr; 7(2):132-156. PubMed ID: 38617189
[TBL] [Abstract][Full Text] [Related]
35. Giving T-cell bispecifics a helping hand.
Kobold S
Blood; 2024 May; 143(21):2115-2116. PubMed ID: 38780922
[No Abstract] [Full Text] [Related]
36. BCMA Directed Bispecific Antibody Induced Tumor Flare in Multiple Myeloma.
Nagarajan C; Eu Jo MW; Martin TG
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38643030
[No Abstract] [Full Text] [Related]
37. Multiple myeloma treatment: one bridge closer.
Lucca LE
Blood; 2023 Nov; 142(21):1763-1764. PubMed ID: 37995107
[No Abstract] [Full Text] [Related]
38. Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma.
Ludwig H; Munshi NC; Terpos E; Schweitzer I; Raje N; Moreau P; Nooka AK
Blood Adv; 2024 May; ():. PubMed ID: 38776433
[No Abstract] [Full Text] [Related]
39. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
[TBL] [Abstract][Full Text] [Related]
40. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
